Search Results
Results 251 - 300 of 2721
< 1 2 3 4 5 6 7 8 9 10 11 >
Aminian Adel - - 2009
BACKGROUND: Myeloperoxidase (MPO) has emerged as a critical mediator in the physiopathology of atherosclerosis from plaque formation and growth until destabilization and rupture leading to acute coronary syndrome (ACS). Using coronary stenting as a model of plaque injury, we aimed to determine the evolution of systemic MPO levels following coronary ...
Tajima Yutaka - - 2009
A 70-year-old man died 1 h after his car was involved in a minor collision with a stationary bus. One month before the accident, he had been diagnosed as having ischemic heart disease due to severe stenosis of the left anterior descending coronary artery (LADCA) by coronary angiography, followed by ...
Menozzi Alberto - - 2009
AIMS: It has been demonstrated that, in comparison with bare-metal stents (BMS), sirolimus-eluting stents (SES) reduce restenosis after the percutaneous revascularization of small coronary arteries, but the long-term clinical outcomes of this treatment have not yet been investigated. METHODS AND RESULTS: The long-term SES-SMART clinical study was a multicentre, prospective, ...
Liu Xiao-Cheng - - 2010
The problem for transmyocardial revascularization is the occlusion of transmural channels. We have developed a novel heparinized basic fibroblast growth factor (bFGF)-incorporating tubular stent by polymer materials of poly D, L-lactic/glycolic acid (PLGA) and polycaprolactone (PCL) with preferable biocompatibility and mechanical elasticity. This study investigated the effect of this new ...
Leibowitz David - - 2009
Mechanical trauma caused by percutaneous coronary intervention is a major factor contributing to subsequent cardiac events, restenosis, and the need for target lesion revascularization (TLR). To minimize this trauma, we developed a Computerized Angioplasty Pressure Sensor and Inflator Device (CAPSID) for gradual inflation. The objective of the present prospective randomized ...
Roukoz Henri - - 2009
BACKGROUND: Several observational reports have documented both increased and decreased cardiac mortality or Q-wave myocardial infarction with drug-eluting stents compared with bare-metal stents. METHODS: We sought to evaluate the safety and efficacy of drug-eluting stents compared with bare-metal stents early after intervention (<1 year) and late (>1 year) among a ...
Rozenman Yoseph - - 2009
Aims: Stent length is a major predictor of restenosis in stable patients undergoing percutaneous coronary intervention (PCI) with bare metal stents (BMS). The effect of stent length is decreased by using drug eluting stents, however, this association had not been previously determined in patients with acute myocardial infarction (AMI). We ...
Tomassini Francesco - - 2009
We describe two cases of severe, multivessel coronary vasospasm that occurred a few months after placement of sirolimus-eluting stents in patients with severe coronary disease, and involved segments not significantly atheromatous and not previously treated. The literature suggests that biocellular interference with the endothelial equilibrium on the part of drugs ...
Bell Brendan - - 2009
The recently described complication of late and very late stent thrombosis with coronary stents has raised the question of when is it safe to stop antiplatelet therapy in the era of drug eluting stents? With several million patients having already had coronary stents implanted worldwide, the importance of an appreciation ...
Sheiban Imad - - 2009
OBJECTIVE: Drug-eluting stents (DESs) are commonly used in patients with unprotected left main (ULM) disease. Although multivessel disease and stenting are frequent in this population, pertinent details on short-term and long-term outcomes are lacking. SETTING AND PATIENTS: We identified consecutive patients with DES treatment for ULM. We distinguished patients presenting ...
Kaminski Karol A - - 2009
Coronary stenting may create local inflammatory reaction. Interleukin 6 effects depend on the presence of soluble receptors (sIL-6R and sgp130) that facilitate or impede interleukin 6 signal transduction. Concentrations of interleukin 6 and its soluble receptors were assessed in aorta and coronary sinus after stenting in optimally treated stable angina ...
Lee W L S - - 2011
We report on the successful use of endothelial progenitor cell (EPC) capture stents in 2 cases of acute myocardial infarction (MI) that was complicated by major bleeding episodes requiring blood transfusion and necessitating early discontinuation of anti-thrombotic/anti-plaletet agents.
Tacoy Gulten - - 2009
BACKGROUND: The aim of this study was to compare direct and conventional stenting procedure in the subacute stable phase on short- and long-term results in patients with ST elevation myocardial infarction. METHODS: Eighty-eight clinically stable ST-segment elevation myocardial infarction (STEMI) patients were enrolled into the study. The patients were classified ...
Ko Dennis T - - 2009
OBJECTIVES: Our main objective was to evaluate the longer-term safety and efficacy of drug-eluting stents (DES) in off-label indications as compared with bare-metal stents (BMS). BACKGROUND: DES are frequently implanted in patients with off-label indications. However, the longer-term safety and effectiveness of DES among patients with off-label indications are not ...
Chevalier Bernard - - 2009
BACKGROUND: The newly developed Nobori coronary stent coated with a bioresorbable polymer, polylactic acid, and the antiproliferative agent Biolimus A9 has the potential to reduce restenosis by suppressing neointima formation. METHODS AND RESULTS: We conducted a randomized (2:1), controlled trial comparing the Biolimus A9-eluting stent Nobori and the paclitaxel-eluting stent ...
Stone Gregg W - - 2009
BACKGROUND: There is no consensus regarding the safety and efficacy of drug-eluting stents, as compared with bare-metal stents, in patients with ST-segment elevation myocardial infarction who are undergoing primary percutaneous coronary intervention (PCI). METHODS: We randomly assigned, in a 3:1 ratio, 3006 patients presenting with ST-segment elevation myocardial infarction to ...
James Stefan K - - 2009
BACKGROUND: The long-term safety and efficacy of drug-eluting coronary stents have been questioned. METHODS: We evaluated 47,967 patients in Sweden who received a coronary stent and were entered into the Swedish Coronary Angiography and Angioplasty Registry between 2003 and 2006 and for whom complete follow-up data were available for 1 ...
Kim Jin Won - - 2009
OBJECTIVES: We prospectively compared coronary endothelial dysfunction in patients with zotarolimus-eluting stent (ZES) versus sirolimus-eluting stent (SES) implantation at 6-month follow-up. BACKGROUND: A ZES has been associated with uniform and rapid healing of the endothelium. METHODS: Fifty patients were randomly treated with intravascular ultrasound-guided stenting with a single stent to ...
Ichikawa Minoru - - 2009
Very late stent thrombosis (VLST), a rare complication of stenting, has been reported to develop more frequently at later than 1 year after the deployment of the drug-eluting stent (DES) compared with the bare-metal stent (BMS). However, the causes for the difference in the incidence remain unknown. Serial angioscopy on ...
Vedat Aytekin - - 2009
Evaluating the efficacy of the Infinnium paclitaxel-eluting coronary stent system with the biodegradable polymer in the treatment of symptomatic coronary artery disease. Total 153 patients were treated with native coronary artery lesion treated with Infinnium paclitaxel-eluting coronary stent system. This study was a single centre, non-randomized, retrospective study. At baseline ...
Nidegger Delphine - - 2009
Since the prospective payment system, health institutions have only specific payments for the emergency care in the emergency room. The direct urgent admissions in coronary care units for acute coronary syndrome (ACS) do not collect this complementary refund. For the patient's stay, hospital is remunerated with fixed national prices which ...
Becker David - - 2009
BACKGROUND: Coronary stent thrombosis is a catastrophic complication of percutaneous coronary intervention. There is a paucity of long-term data regarding the clinical outcome of patients who have suffered stent thrombosis. MATERIAL/METHODS: We sought to assess the long-term clinical outcome of patients who suffered de novo ST-segment elevation myocardial infarction as ...
Ajtay Zénó - - 2009
The concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is increased in patients with coronary heart disease (CHD). The potential effect of percutaneous coronary intervention (PCI) with stent placement on ADMA plasma level in CHD patients has not yet been investigated. Concentrations of ADMA, L-arginine, symmetric ...
Onuma Yoshinobu - - 2009
AIMS: To report the 4-month angiographic and 6-month clinical follow-up in first-in-man study using the tacrolimus-eluting bioabsorbable polymer-coated cobalt-chromium MAHOROBA stent. METHODS AND RESULTS: A total of 47 patients with either stable angina or unstable angina, or silent myocardial ischaemia, based on a de novo coronary stenosis that could be ...
Weisz Giora - - 2009
OBJECTIVES: The aim of this study was to examine the 5-year clinical safety and efficacy outcomes in patients enrolled in the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. BACKGROUND: The SIRIUS trial was a double-blinded randomized study that demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at ...
Park Seung-Jung - - 2009
BACKGROUND: Although intravascular ultrasound (IVUS) guidance has been useful in stenting for unprotected left main coronary artery stenosis, its impact on long-term mortality is still unclear. METHODS AND RESULTS: In the MAIN-COMPARE registry, patients with unprotected left main coronary artery stenosis in a hemodynamically stable condition underwent elective stenting under ...
Carlsson Jörg - - 2009
OBJECTIVES: The aim of this study was to investigate the outcome of bare-metal stents (BMS) versus drug-eluting stents (DES) after on-label as well as off-label use. BACKGROUND: DES lower restenosis rates while not influencing the risk for death and myocardial infarction when used in Federal Food and Drug Administration (FDA)-approved ...
Vaquerizo Beatriz - - 2009
BACKGROUND: Cardiac surgery is the reference treatment for patients with left main (LM) disease, although percutaneous coronary intervention with drug-eluting stents is emerging as a possible alternative. The objective of this registry was to evaluate the 2-year outcome of elective percutaneous coronary intervention for unprotected LM disease with paclitaxel-eluting stents. ...
Pierre-Louis Bredy - - 2009
After thrombolytic therapy with tenecteplase for ST-segment elevation acute myocardial infarction, 376 patients were transferred from their hospital to Westchester Medical Center for percutaneous coronary intervention with stenting. Of 376 patients, 102 (27%) received bare-metal stents and 274 (73%) received drug-eluting stents with sirolimus-eluting or paclitaxel-eluting stents. At 43 months ...
Villa Adolfo - - 2009
The aims of this study were to assess the safety of drug-eluting stent (DES) use and to compare the incidence of in-stent restenosis (ISR) and neointimal hyperplasia formation according to the type of stent implanted (DES vs bare-metal stents [BMS]) in patients who underwent intracoronary bone marrow mononuclear cell transplantation ...
Li Yan - - 2009
BACKGROUND: Numerous studies have compared the outcomes of coronary artery bypass grafting (CABG) surgery and coronary stenting for the treatment of multivessel coronary disease. In 2003, drug-eluting stents were introduced with the hope of reducing restenosis. However, limited information exists on the comparison of drug-eluting stents and CABG surgery. The ...
Chechi Tania - - 2009
BACKGROUND: One of the major predictors of late stent malapposition (LSM) is primary stenting in acute myocardial infarction. However, mechanisms of LSM are still under debate. METHODS: Patients with ST-elevation myocardial infarction (STEMI) and enrolled in the SELECTION trial (38 patients in the paclitaxel-eluting stent, PES, and 35 in the ...
Azzarelli Salvatore - - 2009
Multivessel spontaneous coronary artery dissection is a very rare cause of myocardial ischemia. Its optimal treatment is not yet well defined and is usually tailored to clinical features. We report a case of a postpartum woman with multivessel spontaneous coronary artery dissection and acute myocardial infarction, in whom the drug-eluting ...
Thompson Craig A - - 2009
OBJECTIVES: The purpose of this study was to evaluate the time-dependent vascular and myocardial responses to a second-generation, small vessel (< or =2.5 mm) paclitaxel-eluting stent (PES) platform. BACKGROUND: Small caliber coronary vessels present complex challenges for percutaneous coronary intervention (PCI) and are associated with lower technical success and inferior ...
Tsujita Kenichi - - 2009
Most intravascular ultrasound (IVUS)-identifiable myocardial bridges (MBs) were not appreciated angiographically, especially when they occurred adjacent to fixed proximal obstructive disease. The impact of MB stent placement on clinical outcome was determined in 317 consecutive patients with obstructive left anterior descending coronary artery lesions undergoing coronary stent placement. In these ...
Prunotto M - - 2009
Stent-based delivery of tacrolimus has shown neointimal hyperplasia and restenosis reduction; FK506 is a water insoluble macrolide immunosuppressant. The purpose of this study was to evaluate acute and chronic tissue response to a polymer-free FK506 drug-eluting stent implantation in a porcine coronary artery model. Seventy-eight nonatherosclerotic minipigs underwent successful placement ...
Jilaihawi Hasan - - 2009
Conventional tubular balloon expandable (BE) stent designs are poorly suited to coronary bifurcations, yielding highly variable results. For this reason, intense interest remains and industry development continues for dedicated bifurcation coronary stents to make treatment of such lesions more straightforward. Innovative designs have emerged, some balloon expandable, but also self-expandable, ...
Spinler Sarah A - - 2009
Percutaneous coronary intervention (PCI) with stenting is increasingly being utilized for acute coronary syndromes (ACS), and the debate over the safety and efficacy of drug-eluting stents (DESs) versus bare-metal stents (BMSs) has intensified. The difficulty in consistently assessing stent safety is because of the widespread off-label use in patients with ...
Tamburino Corrado - - 2009
This study sought to assess safety and efficacy of implantation of the Catania Coronary Stent System with Nanothin Polyzene-F (CeloNova BioSciences, Newnan, Georgia) in human coronary arteries with clinical data and comprehensive intracoronary imaging. Novel approaches to modify stents (e.g., bioactive agents, coatings) have been developed to address the limitations ...
Verheye Stefan - - 2009
The aim of this study was to compare, in a randomized multicenter trial, paclitaxel-eluting stents (CoStar, Conor Medsystems, Menlo Park, California) versus pimecrolimus-eluting stents (Corio, Conor Medsystems) versus stents with dual elution of both drugs (SymBio, Conor Medsystems) in native coronary arteries. The CoStar cobalt-chromium reservoir-based stent platform, eluting paclitaxel ...
Chu Chun-Yuan - - 2009
Retained fractured guidewire fragments are rarely encountered during percutaneous coronary intervention, but may cause serious morbidity. We present the case of an 85-year-old man who suffered from this complication. He was successfully treated by coronary stent without peri-procedure complications. Follow-up coronary angiography revealed no in-stent restenosis. Coronary interventionists should know ...
Morton John - - 2009
A 62-year-old woman presented to the emergency department with sudden collapse, intractable ventricular fibrillation, and an inferior wall myocardial infarction (MI). An emergent cardiac catheterization showed a totally occluded right coronary artery (RCA). A bare-metal stent was placed in the stenosis, resulting in thrombolysis in myocardial infarction (TIMI)-III flow with ...
Byrne Robert A - - 2009
AIMS: Long-term polymer residue in the coronary milieu is a consequence of current drug-eluting stent (DES) therapy and has been implicated in late adverse events. We developed a novel polymer-free rapamycin- and probucol-eluting stent (Dual-DES) and compared its efficacy against commercially available permanent polymer-based sirolimus-eluting (SES; Cypher) and zotarolimus-eluting (ZES; ...
Bonello Laurent - - 2009
Drug-eluting stents (DES) have reduced the rate of in-stent restenosis compared with bare-metal stents, but are associated with an increased risk of late stent thrombosis. The proximal left anterior descending artery (LAD) is a large vessel and is considered to be at increased risk of both restenosis and stent thrombosis. ...
Capodanno Davide - - 2009
Recent studies of drug-eluting stents (DES) use in routine clinical practice have led to concern regarding their long-term safety and to questions about the adequacy of current antiplatelet therapy guidelines. This study sought to derivate a risk score for predicting stent thrombosis after drug-eluting stenting. The large single center DES ...
Kim Kyung-Soo - - 2010
We hypothesized that delaying the timing of intra-coronary infusion of G-CSF mobilized stem cell until at least 4 weeks after coronary stenting should avoid the stimulation of vascular smooth muscle cells during the early active cellular proliferative phase, thus decreases in-stent restenosis while preserving the beneficial effect of stem cell ...
Vuurmans Tycho - - 2009
This report describes a case of a critical ostial lesion of a dominant right coronary artery (RCA) in a patient with poor left ventricular function due to a previous anterior infarction and documented late drug-eluting stent thrombosis of the RCA. The precise non-invasive determination of the proximal edge of a ...
Van Der Heyden J - - 2009
In the absence of randomized trials, the optimal management of patients with concomitant carotid and coronary artery disease remains disputable. The initial studies of combined or staged carotid endarterectomy in these patients were conceived in an attempt to reduce perioperative mortality. Although encouraging results have been reported with combined carotid ...
Palombo G - - 2009
AIM: Optimal strategy (staged or combined) for the treatment of patients with concurrent severe carotid and cardiac disease is still controversial. Moreover, carotid artery stenting (CAS), has become a valid alternative to carotid endarterectomy (CEA) and has been proposed for the treatment of cardiac patients. The authors report the preliminary ...
Frazer Jeffrey R - - 2009
OBJECTIVES: To determine the short and intermediate term outcome following systemic venous stent placement in children with congenital heart disease. BACKGROUND: Patients with congenital heart disease are at risk of stenosis or occlusion of systemic veins following indwelling lines or catheterizations. Stent dilation may ameliorate symptoms and open the vessel ...
< 1 2 3 4 5 6 7 8 9 10 11 >